Several FGF23-associated bone diseases are described, and although it is shown that FGF23 is a direct inhibitor of bone mineralization and its overexpression associates with osteomalacia in individuals with normal kidney function, it is unclear how FGF23 contributes to altered skeletal histology in CKD. The gene discussed is FGF23; the disease is chronic kidney disease.